Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings

Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings

Introduction: Azacitidine is one of the hypomethylating agents available for the treatment of elderly patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). It is also used as an appropriate treatment of chronic myelomonocytic leukemia (CMML) in the real life setting. As treat...

Full description

Bibliographic Details
Main Authors: Nikolova D., Yordanov A., Radinov A.
Format: Article
Language:English
Published: Sciendo 2021-10-01
Series:Acta Medica Bulgarica
Subjects:
azacitidine (aza, vidaza®)
monitoring
blood count parameters
toxicity
cytogenetic findings
Online Access:https://doi.org/10.2478/amb-2021-0030

Internet

https://doi.org/10.2478/amb-2021-0030

Similar Items